Major Depressive Disorder

At the Southern California Psychiatry Conference, Jason Kellogg, MD, shares insights into the evolution of the MDD pipeline, with an eye on rapid-acting novel mechanisms.

Psychiatrists debunk 10 common antidepressant myths—placebo claims, addiction fears, suicide risk, overuse, and withdrawal—offering evidence-based guidance.

Largest real-world analysis shows Deep TMS cuts PTSD and depression symptoms in comorbid patients; promising but not FDA-cleared yet.

Phase 3 results show single-dose DT120 lysergide ODT delivers rapid, lasting relief in major depressive disorder with mild, transient adverse effects.

Meta-analysis finds intranasal esketamine boosts remission in MDD and TRD fast, but side effects and short trials leave long-term questions.

Caplyta boosts antidepressants in MDD, showing 2–4 week response with minimal weight, metabolic, and EPS risks.

Let's take a look at the next generation of pharmacotherapies for mood and anxiety disorders.

AbbVie’s short-acting psychedelic bretisilocin shows rapid MADRS drops in phase 2a MDD trials, hinting at scalable, supervised depression care.

Post hoc SUSTAIN-1 data reveal who relapses after stopping intranasal esketamine in TRD—key risk factors guide personalized relapse-prevention plans.

Phase 2 trial shows elunetirom rapidly eases bipolar depression symptoms with strong response, good tolerability, and FDA Fast Track momentum.

Yale psychiatrists test esketamine vs IV ketamine for resistant depression, probing long-term safety, side effects, and misuse in real-world care.

Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.

A phase 2b/3 trial of Forvisirvat in major depressive disorder is investigating potential sex-specific antidepressant effects in women.

Clinicians explore transdiagnostic anhedonia—reward learning, loneliness, and digital rewards—offering practical ideas to personalize treatment.

New real-world data in obese, antidepressant-naive patients with MDD shows bupropion edging SSRIs on remission, though rates stay low.

Experts discuss ketamine safety, monitoring, neurotoxicity concerns, and key considerations for psychiatrists treating depression at the ASCP Annual Meeting.

Researchers at the ASCP Annual Meeting reported on how impaired brain insulin signaling may predict worsening depression severity and the links between metabolism and mood.

Real-world registry data reveals young adults with mood disorders face high TD burden yet low diagnosis rates, spotlighting urgent screening gaps.

Massive Lancet meta-analysis suggests most use of antidepressants while pregnant does not raise autism or ADHD risk after confounders, easing treatment decisions.

How antidepressant myths can raise suicide risk—and what evidence-based prescribing, tapering, and crisis supports really look like.

Anti-inflammatory drugs ease anhedonia and depressive symptoms in high-CRP depression, spotlighting CRP-guided treatment and lifestyle strategies while calling for stronger RCTs.

Large meta-analysis finds GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity.

Online tool personalizes antidepressant choice in primary care, cutting dropouts and improving 24-week depression and anxiety scores.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.